The Future of AstraZeneca

The Business, Innovation and Skills Committee took evidence on Pfizer's proposed takeover of AstraZeneca on Tuesday 13 May 2014.


What's on

Date Business

No business announced


  • Close


    • Reports and associated evidence – Reports of Committee inquires. This category may also include Special Reports where they are used by a Committee to bring matters relating to conduct of its business to the notice of the House.
    • Responses to Reports - Responses may be published as a Special Report, or as a Command Paper. They may also be appended to a Report should the Committee have substantial comments on the Response, in which case they can be found listed under Reports. 
    • Other oral and written evidence - Evidence taken by the Committee that has yet to or did not result in the publication of a Report. This includes transcripts of recent meetings.
    • Estimate Memoranda - An Estimate memorandum is an explanatory note that accompanies a government department’s estimate (a means by which a department seeks authority from Parliament for its spending plans).
    • Correspondence - Correspondence sent from or received by the Committee or its Chair.
  • 13 May 2014 - The future of AstraZeneca - oral evidence | PDF version (PDF514 KB) HC 1286 | Published 14 May 2014

    Evidence given by Tony Burke, Assistant General Secretary, Unite, Allan Black, National Officer, GMB (at 09:30); Ian Read, Chairman and Chief Executive, Pfizer Inc., Frank D'Amelio, Executive Vice President, Business Operations and Chief Financial Officer, Pfizer Inc., Jonathan Emms, UK Managing Director, Pfizer Inc. (at 10:00); Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca plc, Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development, AstraZeneca plc, Dr Jane Osbourn, Vice President, R&D Medlmmune Cambridge (at 11:15); Rt Hon. Dr Vince Cable MP, Secretary of State for Business, Innovation and Skills (at 13:00).